Cyxone receive ethical and regulatory approval from Georgia to conduct clinical Phase 2b study in RA
Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (LEPL regulation Agency for Medical and Pharmaceutical Activities) and local Ethics Committees in Georgia to conduct a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).APPRAIS is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with